Crown Bioscience Inc.
Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology
Presentation of Posters by Expert Scientists Now Available On-Demand on Crown Bioscience's Website https://www.crownbio.com/eortc17-posters
SANTA CLARA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, releases scientific posters narrated by leading scientists . These posters were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and are now available on-demand on Crown Bioscience's website, https://www.crownbio.com/eortc17-posters .
Crown Bioscience presented more than a dozen scientific posters describing innovations in the field of preclinical cancer research at AACR-NCI-EORTC 2017. The most compelling work is now available on-demand and narrated by Crown Bioscience's scientific experts. The library of poster presentations includes Dr. Henry Li presenting, "Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments" , Dr. Jie Cai describing "The World's Largest, Well-Characterized PDX Collection ", and Dr. Nektaria Papadopoulou detailing the "Interrogation of Checkpoint Inhibitors in Bioluminescent Orthotopic Syngeneic Models of Hepatocellular Carcinoma ", among others.
"I am excited to share Crown Bioscience's cutting-edge research with colleagues that were not able to attend AACR-NCI-EORTC," said Dr. Henry Li, Crown Bioscience's Vice President of Biomarker & Diagnostic Technology. "The work presented will help researchers understand how to identify critical biomarkers and improve evaluation of cancer therapies and immunotherapies."
"Crown Bioscience is committed to making valuable contributions to the scientific community," said Laurie Heilmann, Crown Bioscience's Chief Business Officer. "By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs."
The library of narrated posters can be found on Crown Bioscience's website, https://www.crownbio.com/eortc17-posters .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
DoubleVerify11.12.2018 18:05 | Pressemeddelelse
DoubleVerify and InMobi Unite to Combat Mobile App Fraud
Claroty11.12.2018 15:03 | Pressemeddelelse
Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform
Farmako GmbH11.12.2018 10:01 | Pressemeddelelse
Farmako: Cannabis distributor to become gateway to Europe
Graduate Management Admission Council10.12.2018 16:28 | Pressemeddelelse
The Graduate Management Admission Council Selects Three New Business Schools for Membership
CereSpir Inc.10.12.2018 15:01 | Pressemeddelelse
CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease
Centrient Pharmaceuticals10.12.2018 13:31 | Pressemeddelelse
DSM Sinochem Pharmaceuticals announces its new name - Centrient Pharmaceuticals
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum